HALOHalozyme Therapeutics, Inc.
$110.41+42% 1Y
$110.41
$61.6352 weeks$115.27
The financials
Halozyme Therapeutics, Inc. by the numbers
Halozyme Therapeutics, Inc. (HALO) reported revenue of $481M in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 84% and net income of $230M (48% of revenue). For the full year FY2025, revenue was $1.40B (+38% year on year) and net income $317M. Its largest product in Q2 2026 was Royalty at $308M, 59% of the disclosed total, well ahead of Bulk R Hu PH20 at 11%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $481M | $326M | +48% |
| Gross profit | $402M | $279M | +44% |
| Operating income | $288M | $202M | +42% |
| Net income | $230M | $165M | +39% |
| Diluted EPS | $1.90 | $1.33 | +43% |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $308M | 59% |
| Bulk R Hu PH20 | $60M | 11% |
| Proprietary Products Sales | $55M | 11% |
| Collaborative Agreements | $44M | 8.3% |
| Upfront Fees | $36M | 6.8% |
| Device Partnered Products | $15M | 2.8% |
| Event Based Development And Regulatory Milestone And Other Fees | $5.7M | 1.1% |
| Device Licensing And Development | $2.5M | 0.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $524.7M (+37%)
Bulk R Hu PH20 grew +156% year on yearSales Based Milestone -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$307.7M$307.7Mquarter on quarter +28%year on year +50%+28%+50%
- Bulk R Hu PH20$59.6M$59.6Mquarter on quarter -19%year on year +156%-19%+156%
- Proprietary Products Sales$55.4M$55.4Mquarter on quarter +32%year on year +19%+32%+19%
- Collaborative Agreements$43.7M$43.7Mquarter on quarter +679%year on year +13%+679%+13%
- Upfront Fees$35.5M$35.5Mquarter on quarter n/ayear on year n/an/an/a
- Device Partnered Products$14.6M$14.6Mquarter on quarter -3.1%year on year +24%-3.1%+24%
- Event Based Development And Regulatory Milestone And Other Fees$5.7M$5.7Mquarter on quarter n/ayear on year -77%n/a-77%
- Device Licensing And Development$2.5M$2.5Mquarter on quarter -56%year on year -39%-56%-39%
- Sales Based Milestone$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%